• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Falk Dan Michael

    3/18/26 8:03:42 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials
    Get the next $EVGN alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Falk Dan Michael

    (Last)(First)(Middle)
    10 HAALIYA HASHNIYA ST.

    (Street)
    HERZELIYA4632012

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/18/2026
    3. Issuer Name and Ticker or Trading Symbol
    Evogene Ltd. [ EVGN ]
    3a. Foreign Trading Symbol
    [EVGN]
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option (right to buy ordinary shares)09/15/202309/15/2032Ordinary shares1,800$10.51D
    Stock Option (right to buy ordinary shares)05/11/202405/11/2033Ordinary shares1,800$6.03D
    Stock Option (right to buy ordinary shares)06/13/202506/13/2034Ordinary shares1,800$7.16D
    Stock Option (right to buy ordinary shares) (1)08/18/2035Ordinary shares2,500$1.29D
    Explanation of Responses:
    1. The options reported in this row vest equally on a quarterly basis (25% per quarter) such that they will be fully vested on the one-year anniversary of the August 18, 2025 grant date.
    Remarks:
    Exhibit 24.1 - Power of Attorney.
    /s/ Nitsan Deutsch, attorney-in-fact03/18/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $EVGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVGN

    DatePrice TargetRatingAnalyst
    11/24/2021$8.00 → $7.00Outperform
    RBC Capital
    10/8/2021$7.00Buy
    ROTH Capital
    8/23/2021$8.00Outperform
    RBC Capital
    7/29/2021$10.00Buy
    Aegis Capital
    More analyst ratings

    $EVGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

    Conference will be held at Lisbon, Portugal - March 23–25, 2026 REHOVOT, Israel, March 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced it will be featured as a presenting company at the upcoming BIO-Europe Spring 2026 conference, being held on March 23-25, in Lisbon. Attending the conference on behalf of Evogene will be Dr. Gabi Tarcic, Chief Development Officer and Dr. Olga Nissan, VP Business Development. At the conference, Evogene will present the latest achievements of its pharma division. Dr. Niss

    3/9/26 9:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

    Conference call and webcast: today, March 05, 2026, 9:00 AM ETREHOVOT, Israel, March 5, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the fourth quarter and full year ended December 31, 2025.    Mr. Ofer Haviv, President & CEO of Evogene, stated: "During 2025, we executed a clear and decisive strategic shift. After a comprehensive review of our technology assets, target markets, and capital allocation priorities, we sharpened our focus to drive sustainable long-term value by co

    3/5/26 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Releases CEO Letter to Shareholders

    Updating on Strategic Progress and OutlookREHOVOT, Israel, Feb. 25, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries today issued a Letter to Shareholders from Ofer Haviv, President and Chief Executive Officer. Dear Evogene Shareholders,I am writing to update you on the significant progress Evogene has made over the past year and to outline the strategic transformation we initiated in 2025 to position the company for long-term value creation.During 2025, following a comprehensive review of our technology, markets, and capital

    2/25/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Evogene Ltd

    3 - Evogene Ltd. (0001574565) (Issuer)

    3/18/26 9:23:02 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form 3 filed by Evogene Ltd

    3 - Evogene Ltd. (0001574565) (Issuer)

    3/18/26 8:27:44 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form 3 filed by Evogene Ltd

    3 - Evogene Ltd. (0001574565) (Issuer)

    3/18/26 8:24:25 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    SEC Filings

    View All

    SEC Form 6-K filed by Evogene Ltd

    6-K - Evogene Ltd. (0001574565) (Filer)

    3/5/26 7:00:07 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form 6-K filed by Evogene Ltd

    6-K - Evogene Ltd. (0001574565) (Filer)

    2/25/26 8:00:32 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form D filed by Evogene Ltd

    D - Evogene Ltd. (0001574565) (Filer)

    2/19/26 4:01:05 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital reiterated coverage on EverGen Infrastructure with a new price target

    RBC Capital reiterated coverage of EverGen Infrastructure with a rating of Outperform and set a new price target of $7.00 from $8.00 previously

    11/24/21 7:31:39 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    ROTH Capital initiated coverage on Evogene with a new price target

    ROTH Capital initiated coverage of Evogene with a rating of Buy and set a new price target of $7.00

    10/8/21 8:30:09 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    RBC Capital initiated coverage on EverGen Infrastructure Corp. with a new price target

    RBC Capital initiated coverage of EverGen Infrastructure Corp. with a rating of Outperform and set a new price target of $8.00

    8/23/21 11:09:14 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Leadership Updates

    Live Leadership Updates

    View All

    Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

    The collaboration is supported by a pan-European EUREKA grant, with participation of the Weizmann Institute of Science REHOVOT, Israel and MUNICH, Germany, Feb. 11, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, Systasy Bioscience GmbH, a biotechnology company leveraging proprietary DNA barcoding technology for hyper-multiplexed pathway profiling in patient-derived iPSC models to accelerate drug discovery for complex disorders, and LMU University Hospital Munich, today announced a collaboration aiming to accelerate the devel

    2/11/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board

    Appointments Strengthen Scientific Leadership and Support the Acceleration of ChemPass AI™ for Drug and Ag-Chemical Discovery REHOVOT, Israel, Feb. 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational chemistry company focused on the AI-driven discovery and design of novel small molecules for the pharmaceutical and agricultural industries, today announced the appointment of Prof. John J. Irwin of the University of California, San Francisco (UCSF), and Prof. Dan T. Major of Bar-Ilan University (BIU) to its scientific advisory board (SAB). The

    2/9/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

    REHOVOT, Israel, Dec. 30, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, is pleased to announce the appointment of Dr. Olga Nissan as its Vice President of Business Development, effective as of January 1, 2026. Dr. Nissan is a seasoned biotechnology and pharmaceutical executive with extensive experience in bridging science, business, and funding. She has a proven track record of leading R&D, clinical develop

    12/30/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Financials

    Live finance-specific insights

    View All

    Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

    Conference call and webcast: today, March 05, 2026, 9:00 AM ETREHOVOT, Israel, March 5, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the fourth quarter and full year ended December 31, 2025.    Mr. Ofer Haviv, President & CEO of Evogene, stated: "During 2025, we executed a clear and decisive strategic shift. After a comprehensive review of our technology assets, target markets, and capital allocation priorities, we sharpened our focus to drive sustainable long-term value by co

    3/5/26 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

    Zoom conference call scheduled for March 5, 2026, 9:00 AM ET REHOVOT, Israel, Feb. 19, 2026 /PRNewswire/ -- Evogene Ltd . (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the fourth quarter and full year 2025, on Thursday, March 5, 2026. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).To attend the conference, please register in advance: https://www.veidan-conferencing.com/evogene The entire conference will be

    2/19/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Schedules Third Quarter 2025 Financial Results Release

    Zoom conference call scheduled for November 20, 2025, 9:00 AM ET REHOVOT, Israel, Nov. 6, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the third quarter of 2025, on Thursday, November 20, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To attend the conf

    11/6/25 9:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Evogene Ltd

    SC 13G/A - Evogene Ltd. (0001574565) (Subject)

    10/15/24 6:52:26 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G filed by Evogene Ltd

    SC 13G - Evogene Ltd. (0001574565) (Subject)

    2/14/24 8:30:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G/A filed by Evogene Ltd (Amendment)

    SC 13G/A - Evogene Ltd. (0001574565) (Subject)

    2/11/22 12:15:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials